Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Olanzapine in the treatment of depression with psychotic features: A prospective open-label study
Objective . Depression with psychotic features is a severe subtype of major depression associated with the presence of delusions , hallucinations and specific neurobiological features . Despite clinical consensus and guideline recommendations , data comparing the efficacy of combining antipsychotics with antidepressants compared to antidepressants alone remain inconclusive . The aim of the study was to investigate effectiveness and tolerability of the atypical antipsychotic olanzapine in acute depression with psychotic features . Methods . Seventeen in patients with major depressive disorder with psychosis ( MDDp ) were treated with a combination of an antidepressant and olanzapine for 6 weeks in a prospect i ve open-label study . Depressive and psychotic symptoms , extrapyramidal and general side effects were assessed every 2 weeks . Sixteen patients were eligible for final analysis . Results . The Brief Psychiatric Rating Scale ( BPRS ) showed a 30 % symptom reduction after week 2 , a 45 % symptom reduction after week 4 and no considerable improvement thereafter . Depressive symptoms ( Bech – Rafaelsen Melancholia Scale , BRMS ) receded by 37 % after week 2 and 50 % after week 4 . No extrapyramidal side effects occurred . Conclusion . Olanzapine is effective and tolerable in combination with an antidepressant in an MDDp inpatient sample . The results concur with data supporting good efficacy in negative and depressive symptoms of patients with schizophrenic and schizoaffective diseases
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .